Matthew Scholz is Immusoft’s founder and Chief Executive Officer. His curiosity about how the body attacks invading pathogens and stores the information sparked his idea for Immusoft. He realized that he could modify technology developed by Nobel Laureate David Baltimore to program resting B cells to secrete therapeutic proteins. The modified system is the core of Immusoft’s technology platform, Immune System Programming™. Immusoft, which under Matthew’s leadership is transitioning from a research biotech to a clinical company, has raised capital from the U.S. National Institutes of Health, Peter Thiel’s Breakout Labs, Founders Fund Science, and prominent private investors, including Tim Draper and the former head of preclinical development at Seattle Genetics. Matthew has a degree in computer science. He is a mentor for the Thiel Fellowship, a program that awards grants to some of the brightest scientific minds in the world under age 20.